Search

Your search keyword '"Cortot A"' showing total 3,282 results
Start Over Author "Cortot A"
3,282 results on '"Cortot A"'

3. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based studyResearch in context

Author

Hélène Sarter, Thibaut Crétin, Guillaume Savoye, Mathurin Fumery, Ariane Leroyer, Luc Dauchet, Thierry Paupard, Hugues Coevoet, Pauline Wils, Nicolas Richard, Dominique Turck, Delphine Ley, Corinne Gower-Rousseau, Eric Agoute, Najib Al Ghossaini, Raied Al Hameedi, Myriam Al Khatib, Saria Al Turk, Jean-Marie Andre, Matthieu Antoine, Michel Antonietti, Amar Aouakli, Laura Armengol-Debeir, Ibrahim Aroichane, Fadi Assi, Eric Auxenfants, Alina Avram, Kassem Azzouzi, Damyan Bankovski, Bernard Barbry, Nicolas Bardoux, Philippe Baron, Anne Baudet, Pauline Bayart, Brice Bazin, Arash Bebahani, Jean-Pierre Becqwort, Houssem Ben Ali, Emmanuel Ben Soussan, Coralie Benard, Vincent Benet, Corinne Benguigui, Abdeslam Bental, Sara Bentaleb-Bellati, Isabelle Berkelmans, Jacques Bernet, Karine Bernou, Nathalie Bertiaux-Vandaele, Pauline Bertot, Valérie Bertrand, Emilie Biloud, Nathalie Biron, Benjamin Bismuth, Cyril Blanchard, Maurice Bleuez, Fabienne Blondel, Valérie Blondin, Marius Bobula, Philippe Bohont, Eléonore Boivin, Vanessa Bon Djemah, Eric Boniface, Philippe Bonniere, Pierre Bonvarlet, Arnaud Boruchowicz, Raoul Bostvironnois, Médina Boualit, Ahlem Bouazza, Bruno Bouche, Christian Boudailler, Claude Bourgeaux, Morgane Bourgeois-Fumery, Arnaud Bourguet, Agnès Bourienne, Hamza Boutaleb, Alexis Bouthors, Julien Branche, Franck Brazier, Marie Bridenne, Hélène Brihier, Laura Bril, Philippe Bulois, Pierre Burgiere, Joël Butel, Jean-Yves Canva, Valérie Canva-Delcambre, Florence Cardot, Sandrine Carette, Pierre Carpentier, Michel Cassagnou, Jean-François Cassar, François Castex, Pascale Catala, Stéphane Cattan, Sylviane Catteau, Bernard Caujolle, Gérard Cayron, Catherine Chandelier, Cloé Charpentier, Marthe Chavance-Thelu, Agathe Cheny, Dinu Chirita, Antoine Choteau, Jean-François Claerbout, Pierre-Yves Clergue, Gil Cohen, Marie Colin, Régis Collet, Jean-Frédéric Colombel, Stéphanie Coopman, Lucie Cordiez, Antoine Cortot, Jean Corvisart, Frédéric Couttenier, Jean-François Crinquette, Valérie Crombe, Abdelhakim Daoudi, Vincent Dapvril, Thierry Davion, Sébastien Decoster, Laurent Defontaine, Nicolas Degrave, Aurélien Dejaeger, Richard Delcenserie, Marine Deleplanque, Dorothée Delesalle, Olivier Delette, Thierry Delgrange, Laurence Delhoustal, Jean-Stéphane Delmotte, Sabri Demmane, Guy Deregnaucourt, Constance Deschepper, Jean-Pierre Desechalliers, Patrick Desmet, Pierre Desreumaux, Gérard Desseaux, Philippe Desurmont, Alain Devienne, Eve Devouge, Alex Devroux, Arnaud Dewailly, Sébastien Dharancy, Aude Di Fiore, Emmanuel Diaz, Djamal-Dine Djeddi, Rachid Djedir, Wissam Doleh, Marie-Laure Dreher-Duwat, Richard Dubois, Clothilde Duburque, Frédéric Ducrot, Philippe Ducrotte, André Dufilho, Christian Duhamel, Caroline Dumant-Forest, Jean-Louis Dupas, Frédéric Dupont, Yves Duranton, Arnaud Duriez, Nicolas Duveau, Mohammadi El Farisi, Khalil El Hachkar, Caroline Elie, Marie-Claire Elie-Legrand, Matthieu Eoche, Essmaeel Essmaeel, Dominique Evrard, Jean-Paul Evrard, Armelle Fatome, Karima Fellah-Sekkai, Bernard Filoche, Laurent Finet, Mathilde Flahaut, Camille Flamme, David Foissey, Peggy Fournier, Philippe Foutrein, Marie-Christine Foutrein-Comes, Thierry Frere, Julie Galand, Philippe Gallais, Claudine Gamblin, Serge Ganga, Romain Gerard, Guillaume Geslin, Yves Gheyssens, Salah Ghrib, Thierry Gilbert, Bénédicte Gillet, Denis Godart, Jean-Michel Godchaux, Guetty Goeguebeur, Odile Goria, Frédéric Gottrand, Philippe Gower, Lucien Grados, Brigitte Grandmaison, Marion Groux, Claire Guedon, Loïc Guerbeau, Mathilde Gueroult-Dero, Jean-François Guillard, Laurence Guillem, François Guillemot, Dominique Guimber, Baya Haddouche, Vincent Hautefeuille, Philippe Hecketsweiller, Geneviève Hecquet, Jean-Pierre Hedde, Hassina Hellal, Pierre-Emmanuel Henneresse, Michel Heraud, Sophie Herve, Bruno Heyman, Patrick Hochain, Philippe Houcke, Lucie Houssin-Baillly, Bruno Huguenin, Silviu Iobagiu, Shata Istanboli, Alexsandar Ivanovic, Isabelle Iwanicki-Caron, Eric Janicki, Marine Jarry, Charlotte Jean Bart, Claude Jonas, Julia Jougon, Anne Jouvenet, Naeim Kassar, Fadi Katherin, Alfred Kerleveo, Ali Khachfe, Alfred Kiriakos, Jean Kiriakos, Olivier Klein, Matthieu Kohut, Richard Kornhauser, Demetrios Koutsomanis, Jean-Eric Laberenne, Eric Lacotte, Guy Laffineur, Marine Lagarde, Anouck Lahaye, Arnaud Lalanne, Ambroise Lalieu, Pierre Lannoy, José Lapchin, Michel Laprand, Denis Laude, Christian Le Couteulx, Charles Le Goffic, Alain Le Grix, Jean-Philippe Le Mouel, Pauline Le Roy, Rachida Leblanc, Paul Lecieux, Stéphane Lecleire, Nathalie Leclerc, Jean Ledent, Jean Lefebvre, Pascale Lefilliatre, Céline Legrand, Patrick Lelong, Bernard Leluyer, Caroline Lemaitre, Lucie Lepileur, Antoine Leplat, Elodie Lepoutre-Dujardin, Gabriel Leppeut, Henri Leroi, Maryvonne Leroy, Benoît Lesage, Jocelyn Lesage, Xavier Lesage, Isabelle Lescanne-Darchis, Dominique Lescut, Bruno Leurent, Michel Lhermie, Louise Libier, Bernard Lisambert, Isabelle Loge, Julien Loreau, Alexandre Louvet, Joséphine Lozinguez, Henri Lubrez, Damien Lucidarme, Jean-Jacques Lugand, Olivier Macaigne, Denis Maetz, Dominique Maillard, Hubert Mancheron, Olivia Manolache, Anne-Bérengère Marks-Brunel, Charline Marre, Raymond Marti, Eric Marzloff, Philippe Mathurin, Jacques Mauillon, Vincent Maunoury, Jean-Luc Maupas, Michèle-Ange Medam Djomo, Chloé Melchior, Ziad Melki, B. Mesnard, Patrice Metayer, Lofti Methari, Franck Meurisse, Laurent Michaud, Patricia Modaine, Angélique Monthe, Loïk Morel, Mathilde Morin, Pierre-Eugène Mortier, Perrine Mortreux, Olivier Mouterde, Nicolas Mozziconaci, Jean Mudry, Maria Nachuri, Minh Dung Ngo, Eric N'guyen Khac, Bertrand Notteghem, Vincent Ollevier, Atika Ouraghi, Barriza Oussadou, Dominique Ouvry, Bernard Paillot, Claire Painchart, Nicole Panien-Claudot, Christian Paoletti, Arsène Papazian, Bruno Parent, Jean-Claude Paris, Philippe Patrier, Bernard Pauwels, Mathieu Pauwels, Richard Petit, Muriel Piat, Sandrine Piotte, Christophe Plane, Bernard Plouvier, Eric Pollet, Pierre Pommelet, Daniela Pop, Charlotte Pordes, Gérard Pouchain, Philippe Prades, Jean-Christophe Prevost, Manon Pruit, Gilles Quartier, Anne-Marie Queuniet, Jean-François Quinton, Alain Rabache, Gilles Raclot, Sébastien Ratajczyk, Nicole Reix, Thibaud Renaut-Vantroys, Marine Revillion, Ghassan Riachi, Clémentine Riault, Cécile Richez, Benoît Rimbert, Philippe Robinson, Juan Daniel Rodriguez, Jean Roger, Jean-Marc Roux, Alain Rudelli, Clémence Saingier, Patrick Schlossberg, David Sefrioui, Michel Segrestin, David Seguy, Célik Seminur, François Sevenet, Jean Silvie, Claire Spyckerelle, Nathalie Talbodec, Noémie Tavernier, Henriette Tchandeu, Aurore Techy, Jean-Luc Thelu, Henri Thiebault, Jean-Marie Thorel, Christophe Thuillier, Guillaume Tielman, Manuella Tode, Jean Tonnel, Jean-Yves Touchais, Audrey Toulemonde-Huguet, Pierre Toumelin, Yvan Touze, Léa Tran, Jean-Luc Tranvouez, Nadia Triki, Justine Turpin, Eric Vaillant, Claude Valmage, Dominique Vanco, Nathalie Vandaele-Bertiaux, Hélène Vandamme, Elise Vander Eeken, Etienne Vanderbercq, Philippe Vandermollen, Philippe Vandevenne, Lionel Vandeville, Alain Vandewalle, Jean-Pierre Vanhoove, Audrey Vanrenterghem, Charlotte Vanveuren, Iona Vasies, Guy Verbiese, Juliette Verlynde, Philippe Vermelle, Christine Verne, Gwenola Vernier-Massouille, Perrine Vezelier-Cocq, Juliette Viart, Benoît Vigneron, Marc Vincendet, Jacques Viot, Y.M. Voiment, Jean-Yves Wallez, Michel Wantier, Faustine Wartel, Jean-Christian Weber, Jean-Louis Willocquet, Nathalie Wizla, Eric Wolschies, Tajiogue Yimfor, Oana Zahara, Alberto Zalar, Sonia Zaoui, and Anne Zellweger

Subjects
Inflammatory bowel disease, Incidence, Prevalence, Population-based registry, Crohn’s disease, Ulcerative colitis, Public aspects of medicine, RA1-1270
Abstract

Summary: Background: In industrialized countries, the incidence of inflammatory bowel disease (IBD) appears stabilized. This study examined the incidence and phenotype of IBD in Northern France over a 30-year period. Methods: Including all IBD patients recorded in the EPIMAD population-based registry from 1988 to 2017 in Northern France, we described the incidence and clinical presentation of IBD according to age, sex and time. Findings: A total of 22,879 incident IBD cases were documented (59% (n = 13,445) of Crohn’s disease (CD), 38% (n = 8803) of ulcerative colitis (UC), 3% (n = 631) of IBD unclassified (IBDU)). Over the study period, incidence of IBD, CD and UC was 12.7, 7.2 and 5.1 per 105 person-years, respectively. The incidence of CD increased from 5.1/105 in 1988–1990 to 7.9/105 in 2015–2017 (annual percent change (APC): +1.9%, p

Published
2024
Full Text
View/download PDF

4. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors

Author

Marius Bredon, Camille Danne, Hang Phuong Pham, Pauline Ruffié, Alban Bessede, Nathalie Rolhion, Laura Creusot, Loic Brot, Iria Alonso, Philippe Langella, Lisa Derosa, Alexis B. Cortot, Bertrand Routy, Laurence Zitvogel, Nicola Segata, and Harry Sokol

Subjects
Cancer, gut microbiota, immune checkpoint inhibitor, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Gut microbiota impacts responses to immune checkpoint inhibitors (ICI). A high level of Faecalibacterium prausnitzii have been associated with a positive response to ICI in multiple cancer types. Here, based on fecal shotgun metagenomics data, we show in two independent cohorts of patients with non-small cell lung cancer and advanced melanoma that a high level of F. prausnitzii at baseline is positively associated with a better clinical response to ICI. In MCA205 tumor-bearing mice, administration of F. prausnitzii strain EXL01, already in clinical development for Inflammatory Bowel Disease, restores the anti-tumor response to ICI in the context of antibiotic-induced microbiota perturbation at clinical and tumor transcriptomics level. In vitro, EXL01 strain enhances T cell activation in the presence of ICI. Interestingly, oral administration of EXL01 strain did not induce any change in fecal microbiota diversity or composition, suggesting a direct effect on immune cells in the small intestine. F. prausnitzii strain EXL01 will be evaluated as an adjuvant to ICI in multiple cancers in the near future.

Published
2024
Full Text
View/download PDF

5. Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based study

Author

Agoute, Eric, Al Ghossaini, Najib, Al Hameedi, Raied, Al Khatib, Myriam, Al Turk, Saria, Andre, Jean-Marie, Antoine, Matthieu, Antonietti, Michel, Aouakli, Amar, Armengol-Debeir, Laura, Aroichane, Ibrahim, Assi, Fadi, Auxenfants, Eric, Avram, Alina, Azzouzi, Kassem, Bankovski, Damyan, Barbry, Bernard, Bardoux, Nicolas, Baron, Philippe, Baudet, Anne, Bayart, Pauline, Bazin, Brice, Bebahani, Arash, Becqwort, Jean-Pierre, Ben Ali, Houssem, Ben Soussan, Emmanuel, Benard, Coralie, Benet, Vincent, Benguigui, Corinne, Bental, Abdeslam, Bentaleb-Bellati, Sara, Berkelmans, Isabelle, Bernet, Jacques, Bernou, Karine, Bertiaux-Vandaele, Nathalie, Bertot, Pauline, Bertrand, Valérie, Biloud, Emilie, Biron, Nathalie, Bismuth, Benjamin, Blanchard, Cyril, Bleuez, Maurice, Blondel, Fabienne, Blondin, Valérie, Bobula, Marius, Bohont, Philippe, Boivin, Eléonore, Djemah, Vanessa Bon, Boniface, Eric, Bonniere, Philippe, Bonvarlet, Pierre, Boruchowicz, Arnaud, Bostvironnois, Raoul, Boualit, Médina, Bouazza, Ahlem, Bouche, Bruno, Boudailler, Christian, Bourgeaux, Claude, Bourgeois-Fumery, Morgane, Bourguet, Arnaud, Bourienne, Agnès, Boutaleb, Hamza, Bouthors, Alexis, Branche, Julien, Brazier, Franck, Bridenne, Marie, Brihier, Hélène, Bril, Laura, Bulois, Philippe, Burgiere, Pierre, Butel, Joël, Canva, Jean-Yves, Canva-Delcambre, Valérie, Cardot, Florence, Carette, Sandrine, Carpentier, Pierre, Cassagnou, Michel, Cassar, Jean-François, Castex, François, Catala, Pascale, Cattan, Stéphane, Catteau, Sylviane, Caujolle, Bernard, Cayron, Gérard, Chandelier, Catherine, Charpentier, Cloé, Chavance-Thelu, Marthe, Cheny, Agathe, Chirita, Dinu, Choteau, Antoine, Claerbout, Jean-François, Clergue, Pierre-Yves, Coevoet, Hugues, Cohen, Gil, Colin, Marie, Collet, Régis, Colombel, Jean-Frédéric, Coopman, Stéphanie, Cordiez, Lucie, Cortot, Antoine, Corvisart, Jean, Couttenier, Frédéric, Crinquette, Jean-François, Crombe, Valérie, Daoudi, Abdelhakim, Dapvril, Vincent, Davion, Thierry, Decoster, Sébastien, Defontaine, Laurent, Degrave, Nicolas, Dejaeger, Aurélien, Delcenserie, Richard, Deleplanque, Marine, Delesalle, Dorothée, Delette, Olivier, Delgrange, Thierry, Delhoustal, Laurence, Delmotte, Jean-Stéphane, Demmane, Sabri, Deregnaucourt, Guy, Deschepper, Constance, Desechalliers, Jean-Pierre, Desmet, Patrick, Desreumaux, Pierre, Desseaux, Gérard, Desurmont, Philippe, Devienne, Alain, Devouge, Eve, Devroux, Alex, Dewailly, Arnaud, Dharancy, Sébastien, Di Fiore, Aude, Diaz, Emmanuel, Djeddi, Djamal-Dine, Djedir, Rachid, Doleh, Wissam, Dreher-Duwat, Marie-Laure, Dubois, Richard, Duburque, Clothilde, Ducrot, Frédéric, Ducrotte, Philippe, Dufilho, André, Duhamel, Christian, Dumant-Forest, Caroline, Dupas, Jean-Louis, Dupont, Frédéric, Duranton, Yves, Duriez, Arnaud, Duveau, Nicolas, El Farisi, Mohammadi, El Hachkar, Khalil, Elie, Caroline, Elie-Legrand, Marie-Claire, Eoche, Matthieu, Essmaeel, Essmaeel, Evrard, Dominique, Evrard, Jean-Paul, Fatome, Armelle, Fellah-Sekkai, Karima, Filoche, Bernard, Finet, Laurent, Flahaut, Mathilde, Flamme, Camille, Foissey, David, Fournier, Peggy, Foutrein, Philippe, Foutrein-Comes, Marie-Christine, Frere, Thierry, Fumery, Mathurin, Galand, Julie, Gallais, Philippe, Gamblin, Claudine, Ganga, Serge, Gerard, Romain, Geslin, Guillaume, Gheyssens, Yves, Ghrib, Salah, Gilbert, Thierry, Gillet, Bénédicte, Godart, Denis, Godchaux, Jean-Michel, Goeguebeur, Guetty, Goria, Odile, Gottrand, Frédéric, Gower, Philippe, Grados, Lucien, Grandmaison, Brigitte, Groux, Marion, Guedon, Claire, Guerbeau, Loïc, Gueroult-Dero, Mathilde, Guillard, Jean-François, Guillem, Laurence, Guillemot, François, Guimber, Dominique, Haddouche, Baya, Hautefeuille, Vincent, Hecketsweiller, Philippe, Hecquet, Geneviève, Hedde, Jean-Pierre, Hellal, Hassina, Henneresse, Pierre-Emmanuel, Heraud, Michel, Herve, Sophie, Heyman, Bruno, Hochain, Patrick, Houcke, Philippe, Houssin-Baillly, Lucie, Huguenin, Bruno, Iobagiu, Silviu, Istanboli, Shata, Ivanovic, Alexsandar, Iwanicki-Caron, Isabelle, Janicki, Eric, Jarry, Marine, Bart, Charlotte Jean, Jonas, Claude, Jougon, Julia, Jouvenet, Anne, Kassar, Naeim, Katherin, Fadi, Kerleveo, Alfred, Khachfe, Ali, Kiriakos, Alfred, Kiriakos, Jean, Klein, Olivier, Kohut, Matthieu, Kornhauser, Richard, Koutsomanis, Demetrios, Laberenne, Jean-Eric, Lacotte, Eric, Laffineur, Guy, Lagarde, Marine, Lahaye, Anouck, Lalanne, Arnaud, Lalieu, Ambroise, Lannoy, Pierre, Lapchin, José, Laprand, Michel, Laude, Denis, Le Couteulx, Christian, Le Goffic, Charles, Le Grix, Alain, Le Mouel, Jean-Philippe, Le Roy, Pauline, Leblanc, Rachida, Lecieux, Paul, Lecleire, Stéphane, Leclerc, Nathalie, Ledent, Jean, Lefebvre, Jean, Lefilliatre, Pascale, Legrand, Céline, Lelong, Patrick, Leluyer, Bernard, Lemaitre, Caroline, Lepileur, Lucie, Leplat, Antoine, Lepoutre-Dujardin, Elodie, Leppeut, Gabriel, Leroi, Henri, Leroy, Maryvonne, Lesage, Benoît, Lesage, Jocelyn, Lesage, Xavier, Lescanne-Darchis, Isabelle, Lescut, Dominique, Leurent, Bruno, Ley, Delphine, Lhermie, Michel, Libier, Louise, Lisambert, Bernard, Loge, Isabelle, Loreau, Julien, Louvet, Alexandre, Lozinguez, Joséphine, Lubrez, Henri, Lucidarme, Damien, Lugand, Jean-Jacques, Macaigne, Olivier, Maetz, Denis, Maillard, Dominique, Mancheron, Hubert, Manolache, Olivia, Marks-Brunel, Anne-Bérengère, Marre, Charline, Marti, Raymond, Marzloff, Eric, Mathurin, Philippe, Mauillon, Jacques, Maunoury, Vincent, Maupas, Jean-Luc, Medam Djomo, Michèle-Ange, Melchior, Chloé, Melki, Ziad, Mesnard, B., Metayer, Patrice, Methari, Lofti, Meurisse, Franck, Michaud, Laurent, Modaine, Patricia, Monthe, Angélique, Morel, Loïk, Morin, Mathilde, Mortier, Pierre-Eugène, Mortreux, Perrine, Mouterde, Olivier, Mozziconaci, Nicolas, Mudry, Jean, Nachuri, Maria, Ngo, Minh Dung, Khac, Eric N'guyen, Notteghem, Bertrand, Ollevier, Vincent, Ouraghi, Atika, Oussadou, Barriza, Ouvry, Dominique, Paillot, Bernard, Painchart, Claire, Panien-Claudot, Nicole, Paoletti, Christian, Papazian, Arsène, Parent, Bruno, Paris, Jean-Claude, Patrier, Philippe, Paupard, Thierry, Pauwels, Bernard, Pauwels, Mathieu, Petit, Richard, Piat, Muriel, Piotte, Sandrine, Plane, Christophe, Plouvier, Bernard, Pollet, Eric, Pommelet, Pierre, Pop, Daniela, Pordes, Charlotte, Pouchain, Gérard, Prades, Philippe, Prevost, Jean-Christophe, Pruit, Manon, Quartier, Gilles, Queuniet, Anne-Marie, Quinton, Jean-François, Rabache, Alain, Raclot, Gilles, Ratajczyk, Sébastien, Reix, Nicole, Renaut-Vantroys, Thibaud, Revillion, Marine, Riachi, Ghassan, Riault, Clémentine, Richard, Nicolas, Richez, Cécile, Rimbert, Benoît, Robinson, Philippe, Rodriguez, Juan Daniel, Roger, Jean, Roux, Jean-Marc, Rudelli, Alain, Saingier, Clémence, Savoye, Guillaume, Schlossberg, Patrick, Sefrioui, David, Segrestin, Michel, Seguy, David, Seminur, Célik, Sevenet, François, Silvie, Jean, Spyckerelle, Claire, Talbodec, Nathalie, Tavernier, Noémie, Tchandeu, Henriette, Techy, Aurore, Thelu, Jean-Luc, Thiebault, Henri, Thorel, Jean-Marie, Thuillier, Christophe, Tielman, Guillaume, Tode, Manuella, Tonnel, Jean, Touchais, Jean-Yves, Toulemonde-Huguet, Audrey, Toumelin, Pierre, Touze, Yvan, Tran, Léa, Tranvouez, Jean-Luc, Triki, Nadia, Turck, Dominique, Turpin, Justine, Vaillant, Eric, Valmage, Claude, Vanco, Dominique, Vandaele-Bertiaux, Nathalie, Vandamme, Hélène, Eeken, Elise Vander, Vanderbercq, Etienne, Vandermollen, Philippe, Vandevenne, Philippe, Vandeville, Lionel, Vandewalle, Alain, Vanhoove, Jean-Pierre, Vanrenterghem, Audrey, Vanveuren, Charlotte, Vasies, Iona, Verbiese, Guy, Verlynde, Juliette, Vermelle, Philippe, Verne, Christine, Vernier-Massouille, Gwenola, Vezelier-Cocq, Perrine, Viart, Juliette, Vigneron, Benoît, Vincendet, Marc, Viot, Jacques, Voiment, Y.M., Wallez, Jean-Yves, Wantier, Michel, Wartel, Faustine, Weber, Jean-Christian, Willocquet, Jean-Louis, Wizla, Nathalie, Wolschies, Eric, Yimfor, Tajiogue, Zahara, Oana, Zalar, Alberto, Zaoui, Sonia, Zellweger, Anne, Sarter, Hélène, Crétin, Thibaut, Leroyer, Ariane, Dauchet, Luc, Wils, Pauline, and Gower-Rousseau, Corinne

Published
2024
Full Text
View/download PDF

6. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study

Author

Ferreira, Marion, Swalduz, Aurélie, Greillier, Laurent, du Rusquec, Pauline, Curcio, Hubert, Raimbourg, Judith, Toffart, Anne-Claire, Gounant, Valérie, Couraud, Sebastien, De Chabot, Gonzague, Friard, Sylvie, Hureaux, José, Jeannin, Gaëlle, Odier, Luc, Ricordel, Charles, Wislez, Marie, Descarpentries, Clotilde, Herbreteau, Guillaume, Missy, Pascale, Morin, Franck, Westeel, Virginie, and Cortot, Alexis B.

Published
2024
Full Text
View/download PDF

7. Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

Author

Swalduz, Aurélie, Beau-Faller, Michèle, Planchard, David, Mazieres, Julien, Bayle-Bleuez, Sophie, Debieuvre, Didier, Fallet, Vincent, Geier, Margaux, Cortot, Alexis, Couraud, Sébastien, Daniel, Catherine, Domblides, Charlotte, Pichon, Eric, Fabre, Elizabeth, Larivé, Sébastien, Lerolle, Ulrike, Tomasini, Pascale, Wislez, Marie, Missy, Pascale, Morin, Franck, Westeel, Virginie, and Auliac, Jean-Bernard

Published
2025
Full Text
View/download PDF

9. MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)‐dependent oncogenic driver in vitro and in humanised HGF knock‐in mice

Author

Marie Fernandes, Brynna Hoggard, Philippe Jamme, Sonia Paget, Marie‐José Truong, Valérie Grégoire, Audrey Vinchent, Clotilde Descarpentries, Angela Morabito, Justas Stanislovas, Enoir Farage, Jean‐Pascal Meneboo, Shéhérazade Sebda, Katia Bouchekioua‐Bouzaghou, Marie Nollet, Sarah Humez, Timothy Perera, Paul Fromme, Luca Grumolato, Martin Figeac, Marie‐Christine Copin, David Tulasne, Alexis B. Cortot, Stéphanie Kermorgant, and Zoulika Kherrouche

Subjects
hepatocyte growth factor, lung cancer, preclinical models, targeted therapies, transcriptomic, tyrosine kinase receptor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Exon skipping mutations of the MET receptor tyrosine kinase (METex14), increasingly reported in cancers, occur in 3–4% of non–small‐cell lung cancer (NSCLC). Only 50% of patients have a beneficial response to treatment with MET‐tyrosine kinase inhibitors (TKIs), underlying the need to understand the mechanism of METex14 oncogenicity and sensitivity to TKIs. Whether METex14 is a driver mutation and whether it requires hepatocyte growth factor (HGF) for its oncogenicity in a range of in vitro functions and in vivo has not been fully elucidated from previous preclinical models. Using CRISPR/Cas9, we developed a METex14/WT isogenic model in nontransformed human lung cells and report that the METex14 single alteration was sufficient to drive MET‐dependent in vitro anchorage‐independent survival and motility and in vivo tumorigenesis, sensitising tumours to MET‐TKIs. However, we also show that human HGF (hHGF) is required, as demonstrated in vivo using a humanised HGF knock‐in strain of mice and further detected in tumour cells of METex14 NSCLC patient samples. Our results also suggest that METex14 oncogenicity is not a consequence of an escape from degradation in our cell model. Thus, we developed a valuable model for preclinical studies and present results that have potential clinical implication.

Published
2023
Full Text
View/download PDF

12. Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

Author

Debieuvre, D., Asselain, B., Cortot, A., Couraud, S., Duval, Y., Falchero, L., Locher, C., Meyer, N., Molinier, O., Morel, H., Templement-Grangerat, D., Tredaniel, J., Olivier, Leleu, Caroline, Clarot, Stéphanie, Martinez, Marie, Bernardi, Etienne, Auvray, Julian, Pinsolle, Chantal, Decroisette, Dorine, Templement, Laure, Belmont, Thierry, Saelens, Amélie, Turlotte, Jérôme, Virally, Reda, Chikouche, Marielle, Sabatini, Sophie, Schneider, Jacky, Crequit, Faraj, Al Freijat, Baihas, Jarjour, Rym, Haouachi, Fethi, El Khanjari, Luc, Stoven, Pascal, Beynel, Vincent, Tack, Fatima, Meniai, Yannick, Duval, Hannah, Ghalloussi-Tebai, Claudia, Rizzo, Waad, Al Sheikh, Marguerite, Lepoulain Doubliez, Florence, Lamotte, François, Christiann, Patrick, Dumont, Philippe, Masson, Fréderic, Bigot, Hervé, Le Floch, Issam, Belhaj, Lionel, Moreau, Stéphanie, Dehette, Antoine, Belle, Lidia, Petit, Thomas, Laurent, Sandrine, Loutski-Vettese, Isabelle, Monnet, Jean-Bernard, Auliac, Edith, Maetz, Jean-Yves, Tavernier, Christian, Delafosse, Pierre-Alexandre, Hauss, Colette, Vincent, Mohamad, Jaafar, Jean Philippe, Kraemer, Laetitia, Chablais, Anne-Sophie, Bravard, Philippe, Bonnefoy, Christine, Lefoll, Alexandra, Bedossa, Élise, Redureau, Acya, Bizieux-Thaminy, Virginie, Levrat, Kevin, Fouet, Claire, Alizon, Cécile, Dujon, Hong, Rabut, Mihai, Popa, Jean, Quieffin, Pierre, Demontrond, Olivier, Molinier, François, Goupil, Kheir Eddine, Benmammar, Vanessa, Pante, Laurent, Portel, Anne-Sophie, Blanchet-Legens, Sébastien, Larive, Jacques, Le Treut, Herve, Pegliasco, Chrystèle, Locher, Séverine, Thomassin, Benoît, Godbert, Cécile, Maincent, Christophe, Perrin, Julie, Obert, Cyril, Maurer, David, Renault, Karim, Amrane, Didier, Debieuvre, Geoffroy, Milliet De Faverges, Andreea, Tudor, Maud, Russier, Hugues, Morel, Hugues, Francois, Jean, Tredaniel, Patrick Aldo, Renault, Magalie, Paysse, Anne-Marie, Chiappa, Romain, Corre, Laurent, Mosser, Sylvie, Julien, David, Nunes, Soraya, Bordier, Eric, Briens, Gwenaëlle, Le Garff, Clothilde, Marty, Bénédicte, Martignac, Charles, Dayen, Emmanuelle, Lecuyer, Philippe, Slaouti, Serge, Jeandeau, Christina, Delmas, Eric, Goarant, Marie, Tiercin, Jean-Michel, Peloni, Joelle, Courdeau-Labourie, Nicolae, Banciu, Anne-Sophie, Bugnet, Olivier, Bylicki, Marjorie, Picaud, Laurence, Thirard, Bertrand, Delclaux, Philippe, Brun, Marion, Nancy, David, Marquette, Gonzague, De Chabot, Pierre, Kuntz, Catherine, Marichy, Lionel, Falchero, Christine, Dussopt, Alexa, Mairovitz, Jean-Marc, Dot, Fanny, Magne, Hoang, T.C.T., Bravard, A.-S., Martinez, S., Le Garff, G., Jeandeau, S., Petit, L., Marquette, D., Amrane, K., Demontrond, P., Tiercin, M., Jarjour, B., Turlotte, A., Masson, P., Jaafar, M., and Hauss, P.-A.

Published
2024
Full Text
View/download PDF

13. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Author

Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A.B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J.-L., Salinas, J., Tomasini, P., Gentzler, R.D., William, W.N., Jr., Reckamp, K.L., Takahashi, T., Ganguly, S., Kowalski, D.M., Bearz, A., MacKean, M., Barala, P., Bourla, A.B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R.E., Bauml, J.M., Campelo, R.G., and Cho, B.C.

Published
2024
Full Text
View/download PDF

18. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

19. Natural Diversity of Cuticular Pheromones in a Local Population of Drosophila after Laboratory Acclimation

Author

Jean-François Ferveur, Jérôme Cortot, Matthew Cobb, and Claude Everaerts

Subjects
5,9-pentacosadiene, 7-pentacosene, 5,9-heptacosadiene, 7-tricosene, Science
Abstract

Experimental studies of insects are often based on strains raised for many generations in constant laboratory conditions. However, laboratory acclimation could reduce species diversity reflecting adaptation to varied natural niches. Hydrocarbons covering the insect cuticle (cuticular hydrocarbons; CHCs) are reliable adaptation markers. They are involved in dehydration reduction and protection against harmful factors. CHCs can also be involved in chemical communication principally related to reproduction. However, the diversity of CHC profiles in nature and their evolution in the laboratory have rarely been investigated. Here, we sampled CHC natural diversity in Drosophila melanogaster flies from a particular location in a temperate region. We also measured cis-Vaccenyl acetate, a male-specific volatile pheromone. After trapping flies using varied fruit baits, we set up 21 D. melanogaster lines and analysed their pheromones at capture and after 1 to 40 generations in the laboratory. Under laboratory conditions, the broad initial pheromonal diversity found in male and female flies rapidly changed and became more limited. In some females, we detected CHCs only reported in tropical populations: the presence of flies with a novel CHC profile may reflect the rapid adaptation of this cosmopolitan species to global warming in a temperate area.

Published
2024
Full Text
View/download PDF

22. Pursuit or discontinuation of anti-PD1 after 2 years of treatment in long-term responder patients with non-small cell lung cancer

Author

Camille Ardin, Sarah Humez, Vincent Leroy, Alexandre Ampere, Soraya Bordier, Fabienne Escande, Amélie Turlotte, Luc Stoven, David Nunes, Alexis Cortot, and Clément Gauvain

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: The optimal duration of immune checkpoint inhibitor (ICI) treatment for patients with advanced non-small cell lung cancer (NSCLC) remains to be determined. Treatment durations in cornerstone phase 3 clinical trials vary between a fixed 2-year duration and pursuit until disease progression. Clinical practices may thus differ according to the attending physician. Objectives: Here we provide real-world data about treatment decisions at 2 years, with subsequent clinical outcomes. Design and Methods: This multicentric observational study included patients with advanced NSCLC whose disease was controlled after 2 years of pembrolizumab or nivolumab. The primary outcome was the decision to discontinue ICI treatment or not, along with factors motivating this decision. Secondary outcomes included progression-free survival (PFS) (according to treatment continuation or not) and adverse events. Results: A total of 91 patients were included, of which 60 (66%) had been pre-treated. The programmed death-ligand 1 expression level was ⩾50% in 43 patients (47%). In 61 patients (67%), ICI was continued after 2 years of treatment. This decision was significantly associated with the care center ( p < 0.001) but neither with the tumor response at 2 years, as evaluated by CT scan or PET scan, nor with clinical status, immune-related adverse events, or previous locally treated oligo-progressive disease under ICI. Two years after the 2-year decision, PFS was 68.5%, [95% confidence interval (CI) (53.3–88.0)] in the ‘ICI discontinuation’ group and 64.1% [95% CI (51.9–79.2)] in the ‘ICI pursuit’ group; hazard ratio for relapse was 1.14 [95% CI (0.54–2.30), p = 0.77]. The overall survival rate at 24 months after discontinuation was 89.2% [95% CI (78.4–100)] for the ‘discontinuation’ group and 93.1% [95% CI (85.8–100)] for the ‘pursuit’ group. Given insufficient power, overall survival could not be compared. Conclusion: The decision to continue ICI or not after 2 years of treatment depends mainly on the care center and does not seem to impact survival. Larger, randomized data sets are required to confirm this result.

Published
2023
Full Text
View/download PDF

23. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Author

Mazieres, J, Drilon, A, Lusque, A, Mhanna, L, Cortot, AB, Mezquita, L, Thai, AA, Mascaux, C, Couraud, S, Veillon, R, Van den Heuvel, M, Neal, J, Peled, N, Früh, M, Ng, TL, Gounant, V, Popat, S, Diebold, J, Sabari, J, Zhu, VW, Rothschild, SI, Bironzo, P, Martinez-Marti, A, Curioni-Fontecedro, A, Rosell, R, Lattuca-Truc, M, Wiesweg, M, Besse, B, Solomon, B, Barlesi, F, Schouten, RD, Wakelee, H, Camidge, DR, Zalcman, G, Novello, S, Ou, SI, Milia, J, and Gautschi, O

Subjects
Lung, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lung Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Oncogenes, Programmed Cell Death 1 Receptor, Progression-Free Survival, Registries, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, immunotherapy, lung cancer, oncogenic addiction, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAnti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.Patients and methodsWe conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.ResultsWe studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Published
2019

24. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

Author

Freijat, Faraj Al, Sheikh, Waad Al, Alizon, Claire, Amrane, Karim, Auliac, Jean-Bernard, Auvray, Etienne, Banciu, Nicolae, Bedossa, Alexandra, Belhaj, Issam, Belle, Antoine, Belmont, Laure, Benmammar, Kheir Eddine, Bernardi, Marie, Beynel, Pascal, Bigot, Fréderic, Bizieux-Thaminy, Acya, Blanchet-Legens, Anne-Sophie, Bonnefoy, Philippe, Bordier, Soraya, Bravard, Anne-Sophie, Briens, Éric, Brun, Philippe, Bugnet, Anne-Sophie, Bylicki, Olivier, Chablais, Laetitia, Chiappa, Anne-Marie, Chikouche, Reda, Christiann, François, Clarot, Caroline, Corre, Romain, Courdeau-Labourie, Joelle, Crequit, Jacky, Dayen, Charles, De chabot, Gonzague, Debieuvre, Didier, Decroisette, Chantal, Dehette, Stéphanie, Delafosse, Christian, Delclaux, Bertrand, Delmas, Christina, Demontrond, Pierre, Dot, Jean-Marc, Dujon, Cécile, Dumont, Patrick, Dussopt, Christine, Duval, Fatima, Khanjari, Fethi El, Falchero, Lionel, Fouet, Kevin, Francois, Hugues, Ghalloussi-Tebai, Yannick, Goarant, Éric, Godbert, Benoît, Goupil, François, Haouachi, Rym, Hauss, Pierre-Alexandre, Jaafar, Mohamad, Jarjour, Baihas, Jeandeau, Serge, Julien, Sylvie, Kraemer, Jean Philippe, Kuntz, Pierre, Lamotte, Florence, Larive, Sébastien, Laurent, Thomas, Floch, Hervé Le, Garff, Gwenaëlle Le, Treut, Jacques Le, Lecuyer, Emmanuelle, Lefoll, Christine, Leleu, Olivier, Doubliez, Marguerite Lepoulain, Levrat, Virginie, Locher, Chrystèle, Loutski-Vettese, Sandrine, Maetz, Edith, Magne, Fanny, Maincent, Cécile, Mairovitz, Alexa, Marichy, Catherine, Marion, Nancy, Marquette, David, Martignac, Bénédicte, Martinez, Stéphanie, Marty, Clothilde, Masson, Philippe, Maurer, Cyril, Meniai, Vincent, De Faverges, Geoffroy Milliet, Molinier, Olivier, Monnet, Isabelle, Moreau, Lionel, Morel, Hugues, Mosser, Laurent, Neidhardt, Anne-Catherine, Nunes, David, Obert, Julie, Pante, Vanessa, Paysse, Magalie, Pegliasco, Herve, Peloni, Jean-Michel, Perrin, Christophe, Petit, Lidia, Picaud, Marjorie, Pinsolle, Julian, Popa, Mihai, Portel, Laurent, Quieffin, Jean, Rabut, Hong, Redureau, Élise, Renault, David, Renault, Patrick Aldo, Rizzo, Claudia, Russier, Maud, Sabatini, Marielle, Saelens, Thierry, Schneider, Sophie, Slaouti, Philippe, Stoven, Luc, Tack, Vincent, Tavernier, Jean-Yves, Templement-Grangerat, Dorine, Thirard, Laurence, Thomassin, Séverine, Tiercin, Marie, Tredaniel, Jean, Tudor, Andreea, Turlotte, Amélie, Vincent, Colette, Virally, Jérôme, Meyer, Nicolas, Duval, Yannick, Asselain, Bernard, Letierce, Alexia, Trédaniel, Jean, Fore, Mathieu, Couraud, Sébastien, and Cortot, Alexis

Published
2022
Full Text
View/download PDF

28. Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors.

Author

Bredon, Marius, Danne, Camille, Pham, Hang Phuong, Ruffié, Pauline, Bessede, Alban, Rolhion, Nathalie, Creusot, Laura, Brot, Loic, Alonso, Iria, Langella, Philippe, Derosa, Lisa, Cortot, Alexis B., Routy, Bertrand, Zitvogel, Laurence, Segata, Nicola, and Sokol, Harry

Abstract

Gut microbiota impacts responses to immune checkpoint inhibitors (ICI). A high level of Faecalibacterium prausnitzii have been associated with a positive response to ICI in multiple cancer types. Here, based on fecal shotgun metagenomics data, we show in two independent cohorts of patients with non-small cell lung cancer and advanced melanoma that a high level of F. prausnitzii at baseline is positively associated with a better clinical response to ICI. In MCA205 tumor-bearing mice, administration of F.prausnitzii strain EXL01, already in clinical development for Inflammatory Bowel Disease, restores the anti-tumor response to ICI in the context of antibiotic-induced microbiota perturbation at clinical and tumor transcriptomics level. In vitro, EXL01 strain enhances T cell activation in the presence of ICI. Interestingly, oral administration of EXL01 strain did not induce any change in fecal microbiota diversity or composition, suggesting a direct effect on immune cells in the small intestine. F. prausnitzii strain EXL01 will be evaluated as an adjuvant to ICI in multiple cancers in the near future. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial

Author

Souquet, Pierre-Jean, Audigier-Valette, Clarisse, Molinier, Olivier, Cortot, Alexis, Margery, Jacques, Moreau, Lionel, Gervais, Radj, Barlesi, Fabrice, Pichon, Eric, Zalcman, Gérard, Dumont, Patrick, Girard, Nicolas, Poudenx, Michel, Mazières, Julien, Cadranel, Jacques, Debieuvre, Didier, Dauba, Jérôme, Langlais, Alexandra, Morin, Franck, Moro-Sibilot, Denis, Westeel, Virginie, and Pérol, Maurice

Published
2022
Full Text
View/download PDF

32. Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

Author

Hoang, T.C.T., primary, Debieuvre, D., additional, Bravard, A.-S., additional, Martinez, S., additional, Le Garff, G., additional, Jeandeau, S., additional, Petit, L., additional, Marquette, D., additional, Amrane, K., additional, Demontrond, P., additional, Tiercin, M., additional, Jarjour, B., additional, Turlotte, A., additional, Masson, P., additional, Jaafar, M., additional, Hauss, P.-A., additional, Morel, H., additional, Asselain, B., additional, Cortot, A., additional, Couraud, S., additional, Duval, Y., additional, Falchero, L., additional, Locher, C., additional, Meyer, N., additional, Molinier, O., additional, Templement-Grangerat, D., additional, Tredaniel, J., additional, Olivier, Leleu, additional, Caroline, Clarot, additional, Stéphanie, Martinez, additional, Marie, Bernardi, additional, Etienne, Auvray, additional, Julian, Pinsolle, additional, Chantal, Decroisette, additional, Dorine, Templement, additional, Laure, Belmont, additional, Thierry, Saelens, additional, Amélie, Turlotte, additional, Jérôme, Virally, additional, Reda, Chikouche, additional, Marielle, Sabatini, additional, Sophie, Schneider, additional, Jacky, Crequit, additional, Faraj, Al Freijat, additional, Baihas, Jarjour, additional, Rym, Haouachi, additional, Fethi, El Khanjari, additional, Luc, Stoven, additional, Pascal, Beynel, additional, Vincent, Tack, additional, Fatima, Meniai, additional, Yannick, Duval, additional, Hannah, Ghalloussi-Tebai, additional, Claudia, Rizzo, additional, Waad, Al Sheikh, additional, Marguerite, Lepoulain Doubliez, additional, Florence, Lamotte, additional, François, Christiann, additional, Patrick, Dumont, additional, Philippe, Masson, additional, Fréderic, Bigot, additional, Hervé, Le Floch, additional, Issam, Belhaj, additional, Lionel, Moreau, additional, Stéphanie, Dehette, additional, Antoine, Belle, additional, Lidia, Petit, additional, Thomas, Laurent, additional, Sandrine, Loutski-Vettese, additional, Isabelle, Monnet, additional, Jean-Bernard, Auliac, additional, Edith, Maetz, additional, Jean-Yves, Tavernier, additional, Christian, Delafosse, additional, Pierre-Alexandre, Hauss, additional, Colette, Vincent, additional, Mohamad, Jaafar, additional, Jean Philippe, Kraemer, additional, Laetitia, Chablais, additional, Anne-Sophie, Bravard, additional, Philippe, Bonnefoy, additional, Christine, Lefoll, additional, Alexandra, Bedossa, additional, Élise, Redureau, additional, Acya, Bizieux-Thaminy, additional, Virginie, Levrat, additional, Kevin, Fouet, additional, Claire, Alizon, additional, Cécile, Dujon, additional, Hong, Rabut, additional, Mihai, Popa, additional, Jean, Quieffin, additional, Pierre, Demontrond, additional, Olivier, Molinier, additional, François, Goupil, additional, Kheir Eddine, Benmammar, additional, Vanessa, Pante, additional, Laurent, Portel, additional, Anne-Sophie, Blanchet-Legens, additional, Sébastien, Larive, additional, Jacques, Le Treut, additional, Herve, Pegliasco, additional, Chrystèle, Locher, additional, Séverine, Thomassin, additional, Benoît, Godbert, additional, Cécile, Maincent, additional, Christophe, Perrin, additional, Julie, Obert, additional, Cyril, Maurer, additional, David, Renault, additional, Karim, Amrane, additional, Didier, Debieuvre, additional, Geoffroy, Milliet De Faverges, additional, Andreea, Tudor, additional, Maud, Russier, additional, Hugues, Morel, additional, Hugues, Francois, additional, Jean, Tredaniel, additional, Patrick Aldo, Renault, additional, Magalie, Paysse, additional, Anne-Marie, Chiappa, additional, Romain, Corre, additional, Laurent, Mosser, additional, Sylvie, Julien, additional, David, Nunes, additional, Soraya, Bordier, additional, Eric, Briens, additional, Gwenaëlle, Le Garff, additional, Clothilde, Marty, additional, Bénédicte, Martignac, additional, Charles, Dayen, additional, Emmanuelle, Lecuyer, additional, Philippe, Slaouti, additional, Serge, Jeandeau, additional, Christina, Delmas, additional, Eric, Goarant, additional, Marie, Tiercin, additional, Jean-Michel, Peloni, additional, Joelle, Courdeau-Labourie, additional, Nicolae, Banciu, additional, Anne-Sophie, Bugnet, additional, Olivier, Bylicki, additional, Marjorie, Picaud, additional, Laurence, Thirard, additional, Bertrand, Delclaux, additional, Philippe, Brun, additional, Marion, Nancy, additional, David, Marquette, additional, Gonzague, De Chabot, additional, Pierre, Kuntz, additional, Catherine, Marichy, additional, Lionel, Falchero, additional, Christine, Dussopt, additional, Alexa, Mairovitz, additional, Jean-Marc, Dot, additional, and Fanny, Magne, additional

Published
2024
Full Text
View/download PDF

34. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

Author

Didier Debieuvre, Olivier Molinier, Lionel Falchero, Chrystèle Locher, Dorine Templement-Grangerat, Nicolas Meyer, Hugues Morel, Yannick Duval, Bernard Asselain, Alexia Letierce, Jean Trédaniel, Jean-Bernard Auliac, Olivier Bylicki, Lionel Moreau, Mathieu Fore, Romain Corre, Sébastien Couraud, Alexis Cortot, Faraj Al Freijat, Waad Al Sheikh, Claire Alizon, Karim Amrane, Etienne Auvray, Nicolae Banciu, Alexandra Bedossa, Issam Belhaj, Antoine Belle, Laure Belmont, Kheir Eddine Benmammar, Marie Bernardi, Pascal Beynel, Fréderic Bigot, Acya Bizieux-Thaminy, Anne-Sophie Blanchet-Legens, Philippe Bonnefoy, Soraya Bordier, Anne-Sophie Bravard, Éric Briens, Philippe Brun, Anne-Sophie Bugnet, Laetitia Chablais, Anne-Marie Chiappa, Reda Chikouche, François Christiann, Caroline Clarot, Joelle Courdeau-Labourie, Jacky Crequit, Charles Dayen, Gonzague De chabot, Chantal Decroisette, Stéphanie Dehette, Christian Delafosse, Bertrand Delclaux, Christina Delmas, Pierre Demontrond, Jean-Marc Dot, Cécile Dujon, Patrick Dumont, Christine Dussopt, Fatima Duval, Fethi El Khanjari, Kevin Fouet, Hugues Francois, Yannick Ghalloussi-Tebai, Éric Goarant, Benoît Godbert, François Goupil, Rym Haouachi, Pierre-Alexandre Hauss, Mohamad Jaafar, Baihas Jarjour, Serge Jeandeau, Sylvie Julien, Jean Philippe Kraemer, Pierre Kuntz, Florence Lamotte, Sébastien Larive, Thomas Laurent, Hervé Le Floch, Gwenaëlle Le Garff, Jacques Le Treut, Emmanuelle Lecuyer, Christine Lefoll, Olivier Leleu, Marguerite Lepoulain Doubliez, Virginie Levrat, Sandrine Loutski-Vettese, Edith Maetz, Fanny Magne, Cécile Maincent, Alexa Mairovitz, Catherine Marichy, Nancy Marion, David Marquette, Bénédicte Martignac, Stéphanie Martinez, Clothilde Marty, Philippe Masson, Cyril Maurer, Vincent Meniai, Geoffroy Milliet De Faverges, Isabelle Monnet, Laurent Mosser, Anne-Catherine Neidhardt, David Nunes, Julie Obert, Vanessa Pante, Magalie Paysse, Herve Pegliasco, Jean-Michel Peloni, Christophe Perrin, Lidia Petit, Marjorie Picaud, Julian Pinsolle, Mihai Popa, Laurent Portel, Jean Quieffin, Hong Rabut, Élise Redureau, David Renault, Patrick Aldo Renault, Claudia Rizzo, Maud Russier, Marielle Sabatini, Thierry Saelens, Sophie Schneider, Philippe Slaouti, Luc Stoven, Vincent Tack, Jean-Yves Tavernier, Laurence Thirard, Séverine Thomassin, Marie Tiercin, Jean Tredaniel, Andreea Tudor, Amélie Turlotte, Colette Vincent, and Jérôme Virally

Subjects
Lung cancer, Smoking habits, Real-life, Tumor characteristics, Adenocarcinoma, Non-small-cell lung cancer, Public aspects of medicine, RA1-1270
Abstract

Summary: Background: Long-term changes in lung cancer (LC) patients are difficult to evaluate. We report results from the French KBP-2020 real-life cohort. Methods: KBP-2020 was a prospective cohort that included all patients diagnosed with LC in 2020, in nonacademic public hospital in France. Patient and tumour characteristics were described and compared with similarly designed cohorts in 2000 and 2010. Findings: In 2020, 82 centers included 8,999 patients diagnosed with LC. The proportion of women increased: 34·6% (3114/8999) compared to, 24·3% (1711/7051) and 16·0% (904/5667) in 2010 and 2000 (p

Published
2022
Full Text
View/download PDF

37. Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d’imagerie thoracique statement paper on lung cancer screening

Author

Couraud, Sébastien, Ferretti, Gilbert, Milleron, Bernard, Cortot, Alexis, Girard, Nicolas, Gounant, Valérie, Laurent, François, Leleu, Olivier, Quoix, Elisabeth, Revel, Marie-Pierre, Wislez, Marie, Westeel, Virginie, Zalcman, Gérard, Scherpereel, Arnaud, and Khalil, Antoine

Published
2021
Full Text
View/download PDF

38. Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR

Author

Cadranel, J., Fallet, V., Baldacci, S., Duruisseaux, M., and Cortot, A.

Abstract

Les mutations de l’EGFR restent aujourd’hui le mécanisme d’addiction oncogénique ciblable le plus fréquemment observé au cours des cancers bronchiques non à petites cellules (CBNPC) étendus, représentant 12 % des adénocarcinomes et 44 % des CBNPC des non-fumeurs, en France. Les mutations « communes » de l’EGFR – délétions de l’exon 19 et mutation L858R de l’exon 21, sont observées dans 89 % des cas. L’utilisation des nouvelles techniques de biologie moléculaire nous confronte à l’identification de mutations « rares» de l’EGFR – en particulier les insertions dans l’exon 20, mais aussi à la constatation d’une hétérogénéité moléculaire au diagnostic et durant le suivi. Cette hétérogénéité d’une part, explique en partie les variations d’efficacité observées des inhibiteurs de tyrosine kinase de l’EGFR (ITK-EGFR) et d’autre part, conduit à l’émergence de clones résistants. L’osimertinib est le standard de 1religne thérapeutique. Cependant, la place de la chimiothérapie associée ou l’émergence de l’amivantamab (anticorps bispécifique EGFR et MET) pourraient modifier l’organisation des séquences thérapeutiques, afin d’obtenir une amélioration de la survie globale, mais au dépend d’une augmentation des toxicités et de ce fait d’un risque de détérioration de la qualité de vie. L’enjeu actuel est de déterminer les populations de patients pouvant justifier d’une combinaison thérapeutique dès la 1religne de traitement.

Published
2024
Full Text
View/download PDF

39. Autres cibles addictives (KRAS, RET, HER2, NTRK...)

Author

Cortot, A., Abdayem, P., and Planchard, D.

Abstract

Le pronostic du cancer bronchique non à petites cellules (CBNPC) s’est nettement amélioré depuis la découverte des altérations moléculaires oncogéniques pouvant être ciblées par des traitements spécifiques comme les inhibiteurs de tyrosine kinase (ITK) et les anticorps conjugués. Aujourd’hui, la recherche de plusieurs altérations moléculaires est fortement recommandée lors du diagnostic de CBNPC non épidermoïde (quel que soit le statut tabagique du patient) et de CBNPC épidermoïde (chez un patient non/ peu fumeur). Les techniques de séquençage de nouvelle génération de l’ADN ou de l’ARN permettent de couvrir simultanément de nombreuses anomalies moléculaires en épargnant le maximum de tissu. Les biopsies liquides gagnent de plus en plus d’ampleur dans l’identification des altérations oncogéniques et des mécanismes de résistance aux thérapies ciblées mais restent moins sensibles que les biopsies tissulaires. Dans cette revue, nous présenterons les dernières données sur les altérations oncogéniques les plus fréquemment décelées dans le CBNPC métastatique à l’exception des mutations EGFR et des réarrangements ALK et ROS1. L’accès aux thérapies innovantes restant limité en standard, la participation aux essais cliniques est vivement encouragée. Nous insistons également sur l’importance des programmes de recherche translationnelle avec biopsies tumorales séquentielles permettant de mieux comprendre les mécanismes d’action et de résistance aux thérapies innovantes.

Published
2024
Full Text
View/download PDF

40. Algorithme thérapeutique des CBNPC sans mutation addictive

Author

Moro-Sibilot, D., Mazières, J., Berardi, G., Pérol, M., and Cortot, A.

Abstract

Le développement en 1religne de l’immunothérapie avec les anti-PD-1 et anti-PD-L1 a transformé l’algorithme de traitement des cancers bronchiques non à petites cellules (CBNPC) avancés. Les associations chimiothérapie et anti-PD (L)-1 s’avèrent supérieures à la chimiothérapie indépendamment du niveau d’expression de PD-L1, constituant le standard thérapeutique lorsque PD-L1 est exprimé dans moins de 50 % des cellules tumorales dans les tumeurs épidermoïdes et non épidermoïdes. Comparativement à la chimiothérapie de 1religne, le pembrolizumab, le cemiplimab et l’atézolizumab améliorent la survie dans les CBNPC exprimant PD-L1 dans plus de 50 % des cellules tumorales. L’apport de la chimio-immunothérapie en cas d’expression de PD-L1 ≥ 50 % reste débattu. La place des combinaisons anti-CTLA-4 + anti-PD(L)-1, ou l’association avec une chimiothérapie de courte durée reste à préciser et ne peuvent être prescrit en France. Le traitement de seconde ligne est actuellement représenté soit par un doublet à base de sels de platine chez les patients traités en monothérapie de première ligne par anti-PD1, soit chez les patients traités par association chimiothérapie-immunothérapie par les chimiothérapies standards de seconde ligne, le docétaxel, quelle que soit l’histologie, ou le pémétrexed pour les carcinomes non épidermoïdes si non utilisé en première ligne. L’addition d’un traitement antiangiogénique aux taxanes améliore modestement la survie des patients. Le bévacizumab a montré son intérêt en association avec le paclitaxel. L’introduction de nouvelles modalités d’immunothérapie, la recherche de nouveaux biomarqueurs d’efficacité et la compréhension des mécanismes de résistance devraient permettre d’améliorer les résultats de ces traitements.

Published
2024
Full Text
View/download PDF

41. Recommandations de l’Intergroupe francophone de cancérologie thoracique, de la Société de pneumologie de langue française, et de la Société d’imagerie thoracique sur le dépistage du cancer bronchopulmonaire par tomodensitométrie à faible dose d’irradiation

Author

Couraud, S., Ferretti, G., Milleron, B., Cortot, A., Girard, N., Gounant, V., Laurent, F., Leleu, O., Quoix, E., Revel, M.-P., Wislez, M., Westeel, V., Zalcman, G., Scherpereel, A., and Khalil, A.

Published
2021
Full Text
View/download PDF

45. Paclitaxel–bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study

Author

Geoffroy Bilger, Anne-Claire Toffart, Marie Darrason, Michaël Duruisseaux, Lucie Ulmer, Pascal Wang, Etienne Giroux Leprieur, Nicolas Girard, Marie Ange Massiani, Paul Bore, Renaud Descourt, Julian Pinsolle, Solene Valery, Isabelle Monnet, Aurélie Swalduz, Claire Tissot, Pierre Fournel, Anne Baranzelli, Alexis B. Cortot, and Chantal Decroisette

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Compared with docetaxel, the phase-III trial, ULTIMATE, showed a significant improvement of progression-free survival (PFS) with paclitaxel–bevacizumab combination (PB) as second- or third-line treatment in advanced non-small cell lung cancer (NSCLC). With the increase of immunotherapy treatment in first-line settings, the optimal treatment after first-line failure must be redefined. Methods: This multicentric retrospective study identified all advanced NSCLC patients treated with PB as second-line therapy and beyond. The main efficacy outcomes assessed were objective response rate (ORR), disease control rate (DCR), PFS, and overall survival (OS). The adverse events were reported according to Common Terminology Criteria for Adverse Events (CTCAE). Results: From January 2010 to February 2020, 314 patients in 16 centers received the PB combination. Most patients were male (55%), with a median age of 60 years (19–82), 95% had adenocarcinoma, 27% had a performance status ⩾2, 45% had brain metastases at the time of inclusion. They mostly received the PB combination either in second (20%) or in third-line (39%), and 28% were treated just after ICI failure. ORR and DCR were 40% and 77%, respectively; median PFS and OS were 5.7 [interquartile range (IQR): 3.2–9.6] and 10.8 [IQR: 5.3–19.6] months, respectively. All grade adverse events concerned 82% of patients, including 53% asthenia and 39% neurotoxicity, and 25% of patients continued monotherapy (mostly with bevacizumab) alone due to toxicity. Median PFS for patients treated after ICI failure (ICI+) was significantly superior compared with those not previously treated with ICI (ICI−): 7.0 [IQR: 4.2–11.0] versus 5.2 [IQR: 2.9–8.8] months, p = 0.01, without statistically significant difference for OS between these two groups. In multivariate analysis, factors associated with superior PFS were previous ICI treatment and performance status of 0–1. Only a performance status of 0–1 was associated with superior OS. Conclusion: PB combination as second-line treatment or beyond for advanced non-squamous NSCLC had acceptable toxicity and a clinically relevant efficacy and is an option as salvage treatment for these patients, more particularly after ICI progression.

Published
2022
Full Text
View/download PDF

47. Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study

Author

MARQUETTE, Charles-Hugo, BOUTROS, Jacques, Benzaquen, Jonathan, FERREIRA, Marion, PASTRE, Jean, Pison, Christophe, PADOVANI, Bernard, BETTAYEB, Faiza, FALLET, Vincent, GUIBERT, Nicolas, BASILLE, Damien, ILIE, Marius, HOFMAN, Véronique, HOFMAN, Paul, ISRAEL-BIET, Dominique, CHABOT, François, GUILLAUMOT, Anne, DESLEE, Gaetan, PEROTIN, Jeanne-Marie, DURY, Sandra, MAL, Hervé, MARCEAU, Armelle, Kessler, Romain, Vergnon, Jean-Michel, Pelissier, Carole, Di Palma, Fabrice, Cuvelier, Antoine, PATOUT, Maxime, Bourdin, Arnaud, GAMEZ, Anne Sophie, ANDREJAK, Claire, POULET, Claire, FRANCOIS, Géraldine, Jounieaux, Vincent, Roche, Nicolas, Jouneau, Stéphane, Brinchault, Graziella, Bonniaud, Philippe, ZOUAK, Ayoub, Scherpereel, Arnaud, BALDACCI, Simon, CORTOT, Alexis, Mornex, Jean François, Steenhouwer, François, LEROY, Sylvie, BERTHET, Jean-Philippe, FONTAS, Eric, BULSEI, Julie, CRUZEL, Coralie, Pradelli, Johanna, Fontaine, Maureen, MANIEL, Charlotte, Griffonnet, Jennifer, BUTORI, Catherine, SELVA, Eric, POUDENX, Michel, AguilanIu, Bernard, Ferretti, Gilbert, Arbib, François, Briault, Amandine, Toffart, Anne-Claire, Dahalani, Raissa, Destors, Marie, Chanez, Pascal, GREILLIER, Laurent, ASTOUL, Philippe, BARLESI, Fabrice, GAUBERT, Jean-Yves, Mazières, Julien, Marchand-Adam, Sylvain, Cadranel, Jacques, CHAABANE, Nouha, IZADIFAR, Armine, ROSENCHER, Lise, RUPPERT, Anne-Marie, VIEIRA, Thibault, MATHIOT, Nathalie, Marquette, Charles-Hugo, Boutros, Jacques, Ferreira, Marion, Pastre, Jean, Padovani, Bernard, Bettayeb, Faiza, Fallet, Vincent, Guibert, Nicolas, Basille, Damien, Ilie, Marius, Hofman, Véronique, and Hofman, Paul

Published
2020
Full Text
View/download PDF

49. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study

Author

Cortot, Alexis B., Audigier-Valette, Clarisse, Molinier, Olivier, Le Moulec, Sylvestre, Barlesi, Fabrice, Zalcman, Gérard, Dumont, Patrick, Pouessel, Damien, Poulet, Claire, Fontaine-Delaruelle, Clara, Hiret, Sandrine, Dixmier, Adrien, Renault, Patrick-Aldo, Becht, Catherine, Raffy, Olivier, Dayen, Charles, Mazieres, Julien, Pichon, Eric, Langlais, Alexandra, Morin, Franck, Moro-Sibilot, Denis, and Besse, Benjamin

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results